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OBJECTIVE: To evaluate the influence of pain on quality of life in breast cancer patients.
METHODS: A cross-sectional study of 400 patients, including 118 without metastasis, 160 with loco-regional
metastasis and 122 with distant metastasis. The instruments used were the European Organization for Research
and Treatment for Cancer Quality of Life Questionnaire-Core 30 and the Breast Cancer-specific 23 and short
McGill Pain Questionnaire.
RESULTS: In total, 71.7% of patients reported pain. The most frequent sensory descriptor used by patients
was ‘jumping.’ In the evaluative dimension, the main descriptor chosen was troublesome. The Global Health
self-assessment showed pain to be inversely correlated with quality of life: the group without metastasis had a
mean score of 55.3 (SD=24.8) for those in pain, which rose to 69.7 (SD=19.2) for those without pain (p=0.001).
Subjects with loco-regional metastasis had score of 59.1 (SD=21.3) when in pain, and those without pain had a
significantly higher score of 72.4 (SD=18.6) (po0.001). Patients from the distant metastasis group showed
similar results with a mean score of 48.6 (SD=23.1) for those in pain and 67.6 (SD=20.4) for those without pain
(p=0.002). Regarding the association of pain intensity and quality of life, patients with distant metastasis and
intense pain had the worst scores for quality of life with a functional scale mean of 49.9 (SD=17.3) (po0.009),
a Symptom Scale score of 50.0 (SD=20.1) (po0.001) and a Global Health Scale score of 39.7 (SD=24.7) (po0.006).
CONCLUSIONS: Pain compromises the quality of life of patients with breast cancer, particularly those with
advanced stages of the disease.
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’ INTRODUCTION
Breast cancer (BC) is often associated with long-term psycho-
logical distress, chronic pain, fatigue and impaired quality of
life (QoL) (1-5). Approximately 20% to 50% of patients com-
plain about pain, a number which rises to 90% for patients in
metastatic or terminal stages (6-10).
Pain is one of the most frequently reported adverse effects
that occurs as part of the disease process or as a side-effect of
treatment. It is a problem for a majority of BC patients and
has an unfavorable effect on QoL (11-15).
More recent epidemiological data obtained from a meta-
analysis suggest that pain is prevalent in 39.3% of cases after
curative treatment, 55.0% during cancer treatment, and in
66.4% in advanced or terminal stages of the disease (10).
The frequency of pain increases as the disease progresses,
causing physical, emotional, spiritual and functional discomfort.
This impedes performance of daily activities and disturbs sleep-
ing and eating habits. As a result, cognitive function is impaired
and affective, sexual and family relationships are strained,
and work and leisure activities are difficult. This leads to
greatly decreased QoL for these women (9).
Pain is understood as a complex multidimensional expe-
rience that must be evaluated in its affective and cognitive
dimension. Emotional and cognitive factors have a strong
influence on pain perception (16-18); however, untreated
pain affects physical, psychological, social and spiritual well-
being (19,20).
Pain is a stressful, individual and subjective human expe-
rience and has been associated with feelings of social isola-
tion (21); thus, evaluating pain is one of the most challenging
areas of care for this type of patient. The ability to accurately
measure and interpret pain through valid and reliable tools
or instruments may be clinically important in determining
medical protocol and non-pharmaceutical interventions (22).
The purpose of this study was to evaluate the influence of
pain on the QoL of women with BC. A detailed evaluation
of pain enables caretakers to create a strategy to reduce pain
and prevent any secondary symptoms, which improves
patient QoL.
’ MATERIALS AND METHODS
This prospective study was conducted with 400 women
diagnosed with BC undergoing chemotherapy, radiotherapy,
surgery, hormone therapy, or exclusively in palliative care.DOI: 10.6061/clinics/2017(12)07
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The study occurred in the oncology center at a referral hospital
in a medium-sized city in the northeast of Brazil from July 2014
to April 2015. Patients were selected through non-probability
sampling, and patient interviews were conducted during
appointments or in the chemotherapy infusion room.
A patient was considered eligible for the study if they were
diagnosed with BC, undergoing treatment for the disease
or exclusively in palliative care, and were over 18. Women
without cognitive ability and/or verbalization, patients
who had not started treatment, and those who had been
previously diagnosed with depression were excluded.
Three study groups were created within the sample: 1-118
patients without metastasis (MTX), 2- 160 patients with loco-
regional MTX and 3- 122 patients with distant MTX.
Ethical issues were considered, and the Local Research
Ethics Committee approved the present study (no. CAAE
17956113.9.0000.5293) in compliance with the Declaration of
Helsinki and Resolution 466/12 of the Brazilian National
Health Council, which addresses research on human beings.
Before starting the interview, the study objectives were
explained, and the patients participating in the study were
asked to sign a free and informed consent form. This ensured
that participation was voluntary and that answers would be
kept anonymous and confidential.
Pain was evaluated using the Short-Form McGill Pain
Questionnaire (SF-MPQ) proposed by Melzack (23) and
validated in Portuguese by Ferreira et al. (24). This version
consists of 15 pain descriptors belonging to its three dimen-
sions: Sensory (throbbing, jumping, flashing, sharp-pricking,
tugging, burning, spreading, sore/aching), Affective (tiring-
exhausting, sickening, suffocating, frightful-blinding, nagging)
and Evaluative (troublesome, unbearable).
These descriptors were classified as ‘‘present’’ or ‘‘absent.’’
In addition to these descriptors, the instrument also inte-
grates a Numeric Pain Rating Scale. The level of pain intensity
was classified as mild, moderate and severe. These levels were
based on the intensity with which each patient classified their
pain on the Numerical Scale. Thus, 1 to 3 represents mild pain,
whereas 4 to 6 represents moderate pain and 7 to 10 intense
pain. The questionnaire also includes a Body Diagram to
determine the location of the pain referred to by the subjects.
To assess QoL, the European Organization device for Research
and Treatment for Cancer Questionnaire-Core 30 (EORTC
QLQ-C30) was used. This questionnaire is a valid and reliable
evaluation of cancer patient QoL and has been considered
useful in many clinical trials and studies. The EORTC QLQ-C30
(version 3.0) is composed of 30 items, embedded in three scales,
corresponding to the patient’s condition in the past week.
The first scale, the Functional Scale, consists of five domains:
physical, emotional, social, cognitive, and role functioning.
The second scale, the Scale of Symptoms, consists of three
sub-scales (pain, fatigue, nausea and vomiting) and six single
items (dyspnea, sleep disorders, loss of appetite, constipation,
diarrhea, and financial difficulties) and finally, the Global
health scale.
Questions 1-28 are answered on a four-point scale, with each
item classified from none (score value=1) to very much (score
value=4). Questions 29 and 30 are answered on a seven-point
scale going from bad (score value=1) to good (score value=7).
All itemswere then linearly transposed onto a scale from 0 to 100.
For the five functional scales and global health scale, a higher
score indicates a higher level of functioning or overall QoL.
Conversely, for the symptom scale and single items, a higher
score implies a higher level of symptoms or problems (25).
A second questionnaire associated with the EORTC QLQ-
C30, also translated and validated for use in Portuguese, was
used to evaluate QoL. This instrument, EORTC BR23, is
specifically used for BC patients and consists of 23 questions
answered on a 4-point scale (from 1 to 4). It is composed of
two scales: the Functional Scale composed of 4 sub-items
(body image, sexual function, sexual pleasure and future
perspectives) and the Symptom Scale consisting of 4 sub-
items (side effects of systemic therapy, breast symptoms, arm
symptoms and hair loss) (26). The use of these questionnaires
was authorized both by Ferreira et al. (24) and the EORTC
group. All procedures required by the organization were
conducted. Additionally, the Karnofsky Performance Status
(KPS) was used to evaluate functional capacity.
A descriptive analysis of the qualitative variables was
performed through the absolute and relative frequency
distribution. The T-test for independent samples was used
to compare the mean total scores of the EORTC QLQ-C30
and BR23 variables for pain in the three groups of cancer
patients. An analysis of variance (ANOVA) was performed
to identify any existing correlations between all collected
variables. Then, the Tukey test was applied to evaluate the
magnitude of the latter. A significance level of 5% was used,
and all calculations were performed using SPSS.V.13.
’ RESULTS
Evaluating the sociodemographic profile of the 400 women,
we see that most women were between 51 to 60 years of age
(28.8%) or 41 to 50 (28%), and 60% were from the countryside.
Other sociodemographic characteristics show that more than
half, or 54.8%, had only received an elementary school educa-
tion, 51% were married, only 39.3% were on sick leave, and
Catholicism predominated in 63.3% of the patients. Concerning
clinical variables, 87% of the women had a tumor with the
histological appearance of invasive ductal carcinoma, 40% had
loco-regional MTX, 76.5% had undergone some prior treatment
[surgery (68.5%), chemotherapy (52.5%), radiation (22.3%),
hormonal therapy (29.3%) and/or therapywith bisphosphonates
(12.8%)], and 99% were undergoing some type of treatment
[(surgery--late post-surgery (4%), chemotherapy (70%), radio-
therapy (4%), hormonal therapy (25.3%), and/or therapy with
bisphosphonates (19,8%)] at the time of the interview.
Table 1 describes the characteristics of pain, a common
complaint among the women (71.7%). Pain was generally
reported as diffuse in the three groups of patients. Those who
reported pain in more than one site had some form of MTX
(36.5% with loco-regional MTX and 45.7% with distant
MTX). Interestingly, pain in the upper limbs was more
prevalent in patients without MTX.
Table 1 also addresses the nature of pain, classifying it
according to the frequency of sensory descriptors. For the
group without MTX, words such as jumping (70.1%), sore/
aching (65.7%) and sharp-pricking (61.2%) were most common.
For loco-regional MTX, the subjects described the pain as
jumping (80.9%), sore/aching (67.0%) and sharp-pricking
(63.5%), whereas patients with distant MTX described it as
sore/aching (74.3%), jumping (73.3%) and spreading (66.7%).
Within the affective dimension, the most common descrip-
tors for the group without MTX were sickening (61.2%) and
nagging (59.7%). The loco-regional MTX group described it
as tiring-exhausting (62.6%) and nagging (60.0%); likewise,
the distant MTX group preferred words such as tiring-
exhausting (80.0%) and nagging (75.2%). In the evaluative
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dimension, the main descriptor chosen by BC patients was
‘‘troublesome’’ for those without MTX (70.1%), loco-regional
MTX (83.5%) and distant MTX (90.5%).
Table 2 displays the correlations found between the presence
of pain and the different QoL domains (EORTC QLQ-C30
questionnaire): Women who reported pain obtained signifi-
cantly different scores from those who had no complaints of
pain. In the MTX-free group, the mean symptom scores for
patients with pain and without pain were 29.0 (SD=15.3) and
13.4 (SD=10.8), respectively (po0.001). The mean Global Health
score for patients with pain was 55.3 (SD=24.8), whereas it was
69.7 (SD=19.2) for those without pain (p=0.001). For the loco-
regional MTX group, the mean symptom score for patients
with pain was 29.0 (SD=15.3), whereas those without pain had
an average score of 13.4 (SD=10.8) (po0.001). On the Global
Health Scale, patients in pain scored 59.1 (SD=21.3), and those
without pain scored 72.4 (SD=18.6) (po0.001). For the group
with distant MTX, the mean symptom scores for patients with
pain and without pain were 39.6 (SD=19.5) and 17.5 (SD=10.0),
respectively (po0.001). On the Global Health Scale, the mean
score for those reporting pain was 48.6 (SD=23.1), whereas the
mean score for those without pain was 67.6 (SD=20.4)
(p=0.002). It is important to highlight that the higher the score
on the symptom scale, the more symptoms were listed by the
patient, thus compromising their QoL.
Table 2 also shows us that the presence of pain signifi-
cantly influences QoL in BC patients when evaluated by
EORTC BR23. For patients with distant MTX, those who
reported pain had a mean of 56.4 (SD=19.4), whereas those
without pain had a mean of 68.4 (SD=13.9) (p=0.016). Patients
without pain had a better score on self-image evaluation, thus
demonstrating how pain can influence self-esteem and how
the limbic system influences pain. On the Symptom Scale, the
same group of patients obtained a mean of 26.9 (SD=14.2) for
those who were in pain and an average of 16.5 (SD=13.8) for
those without pain (p=0.006).
Table 3 not only displays the relationship between pain
and QoL but also a possible association between pain
intensity and better or worse QoL. Patients with distant
MTX who rate their pain as ‘‘intense’’ are those with the
worst scores on the QoL assessment, with a mean functional
score of 49.9 (SD=17.3) (po0.009), a mean symptom score of
Table 1 - Intensity and dimension of Pain in breast cancer
patients.








N (%) N (%) N (%) N (%)
Yes 67 (56.8) 115 (71.9) 105 (86.1) 287 (71.7)
No 51 (43.2) 45 (28.1) 17 (13.9) 113 (28.3)
Total 118 (100.0) 160 (100.0) 122 (100.0) 400 (100.0)
Location
Upper limb 19 (28.4) 27 (23.5) 05 (4.8) 51 (17.8)
Chest 12 (17.9) 20 (17.4) 07 (6.7) 39 (13.6)
Column 00 (0.0) 03 (2.6) 09 (8.6) 12 (4.2)
In two locations 24 (35.8) 42 (36.5) 48 (45.7) 114 (39.7)
Diffuse 12 (17.9) 23 (20.0) 36 (34.3) 71 (24.7)
Total 67 (100.0) 115 (100.0) 105 (100.0) 287(100.0)
Dimension*
Sensory
Throbbing 34 (50.7) 63 (54.8) 54 (51.4) 151 (52.6)
Jumping 47 (70.1) 93 (80.9) 77 (73.3) 217 (75.6)
Flashing 22 (32.8) 34 (29.6) 48 (45.7) 104 (29.8)
Sharp-pricking 41 (61.2) 73 (63.5) 57 (54.3) 171 (59.6)
Tugging 36 (53.7) 67 (58.3) 53 (50.5) 156 (54.3)
Burning 26 (38.8) 44 (38.3) 44 (41.9) 114 (39.7)
Spreading 27 (40.3) 50 (43.5) 70 (66.7) 147 (51.2)
Sore/aching 44 (65.7) 77 (67.0) 78 (74.3) 199 (69.3)
Affective
Tiring-exhausting 37 (55.2) 72 (62.6) 84 (80.0) 187 (65.1)
Sickening 41 (61.2) 68 (59.1) 68 (64.8) 177 (61.7)
Suffocating 14 (20.9) 10 (8.7) 29 (27.6) 53 (18.5)
Frightful-blinding 14 (20.9) 14 (12.2) 27 (25.7) 55 (19.2)
Nagging 40 (59.7) 69 (60.0) 79 (75.2) 188 (65.5)
Evaluative
Troublesome 47 (70.1) 96 (83.5) 95 (90.5) 238 (82.9)
Unbearable 06 (9.0) 14 (12.2) 25 (23.8) 45 (15.7)
Metastasis = MTX * Counted only for patients with pain.
Table 2 - Correlation between the presence of Pain and Quality




Mean SD Mean SD
Without MTX
Functional Scales 59.8 19.8 76.9 14.7 o0.001*
Physical functioning 69.9 21.4 84.4 16.0 o0.001*
Role functioning 37.1 32.0 60.4 32.3 o0.001*
Cognitive functioning 65.9 31.8 81.7 20.1 0.001*
Emotional functioning 47.0 29.3 65.7 25.6 o0.001*
Social functioning 77.1 32.8 91.8 19.2 0.003*
Symptom Scales 29.0 15.3 13.4 10.8 o0.001*
Global Health Scales 55.3 24.8 69.7 19.2 0.001*
Loco-regional MTX
Functional Scales 63.9 17.5 74.7 15.4 o0.001*
Physical functioning 69.7 21.4 78.5 22.4 0.023*
Role functioning 38.8 30.1 53.7 34.2 0.008*
Cognitive functioning 75.5 26.1 83.0 19.9 0.055
Emotional functioning 55.6 29.1 68.5 25.4 0.010*
Social functioning 79.8 28.7 89.2 18.8 0.017*
Symptom Scales 29.0 15.3 13.4 10.8 o0.001*
Global Health Scales 59.1 21.3 72.4 18.6 o0.001*
Distant MTX
Functional Scales 54.1 17.4 73.1 17.5 o0.001*
Physical functioning 54.0 27.4 74.5 23.9 0.004*
Role functioning 27.1 31.3 53.9 36.1 0.002*
Cognitive functioning 70.5 30.2 79.4 23.9 0.249
Emotional functioning 47.9 27.7 70.1 29.0 0.003*
Social functioning 77.1 29.6 88.2 20.2 0.061
Symptom Scales 39.6 19.5 17.5 10.0 o0.001*
Global Health Scales 48.6 23.1 67.6 20.4 0.002*
EORTC BR23
Without MTX
Functional Scales 56.6 20.2 67.8 15.7 0.001*
Body image 68.8 30.9 84.3 22.1 0.002*
Sexual functioning 26.1 27.9 27.8 28.8 0.753
Sexual enjoyment 51.0 32.8 58.7 31.4 0.400
Future perspective 31.3 37.1 47.1 39.5 0.029*
Symptom Scales 30.9 18.5 13.0 13.0 o0.001*
Loco-regional MTX
Functional Scales 61.1 17.4 71.0 12.0 o0.001*
Body image 73.5 27.5 87.0 17.4 o0.001*
Sexual functioning 29.1 29.5 21.8 28.6 0.159
Sexual enjoyment 59.0 35.4 56.4 28.5 0.812
Future perspective 39.7 39.5 65.2 41.0 o0.001*
Symptom Scales 29.0 15.3 13.4 10.8 o0.001*
Distant MTX
Functional Scales 56.4 19.4 68.4 13.9 0.016*
Body image 68.2 32.7 86.3 18.8 0.003*
Sexual functioning 23.8 26.0 26.5 27.0 0.697
Sexual enjoyment 47.9 30.6 62.5 21.4 0.203
Future perspective 36.2 39.3 49.0 33.6 0.205
Symptom Scales 26.9 14.2 16.5 13.8 0.006*
Metastasis = MTX * T-test.
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50.0 (SD=20.1) (po0.001) and a Global Health Scale mean
of 39.7 (SD=24.7) (po0.006). Functional capacity assessed
by the KPS also showed a significant correlation between
increased pain intensity and decreased QoL. The latter was
observed in all three groups of patients. Women with distant
MTX who reported intense pain obtained a mean KPS of
69.0 (SD=13.9) whereas mild pain reports reached a mean
KPS of 78.9 (SD=8.7) (po0.040).
Pain intensity was also evaluated by EORTC BR23, as
shown in Table 4. Patients with distant MTX who defined
their pain as ‘‘intense’’ scored worse on the Symptom Scale
when evaluating QOL, with a mean of 32.1 (SD=14.8) (p=0.012).
This same association was also observed in the sub-item related
to ‘‘symptoms of the arm’’ with a mean of 40.7 (SD=29.4)
(p=0.001).
’ DISCUSSION
Pain is one of the most common and distressing symptoms
experienced by cancer patients. Cancer pain involves physical,
social, psychological and spiritual components, all of which
belong to the term ‘‘total pain’’, which is used to refer to
the multidimensional nature of pain (Cicely Saunders).
The contribution of each component varies based on both
individual factors and circumstances faced by the patient.
Therefore, the perception of pain is affected by several
variables such as fatigue, insomnia, fear, anxiety, anger,
sadness, depression, social isolation, altered perception of
self-image and impairment of functional capacity (27).
The occurrence of pain may be due to the disease process
itself or as treatment aftermath, such as post-mastectomy
pain, chemotherapy-induced neuropathy or brachial plexus
neuropathy from radiation therapy (28-30). This makes pain
a significant problem for most women with BC, causing a
negative effect on QoL.
Despite cancer pain having been very prevalent in this
study (71.7% of all groups), even in the non-metastatic group
(56.8), the heterogeneity of sociodemographic and clinical
characteristics of the subjects did not allow a specific statis-
tical additional comparison between groups. This result was
similar to that found by Tamai et al. (31), Nabila et al. (19),
and Starkweather et al. (13). Most patients in the sample had
distant MTX, which agrees with the literature wherein bone,
along with the lungs, is one of the major sites affected by
metastatic BC (32,33). In a recent cohort study (34), bone was
found to be the first site for metastatic development in 41%
of the women. Bone MTX are considered the main cause
of cancer pain, impairing functional capacity and limiting
QoL (28,32,35).
The use of descriptors in the evaluation of pain has been
increasingly considered pertinent to research and everyday
clinical practice. These words help professionals determine
type of pain and appropriate therapy to provide patients
with the most pain relief and QoL possible (36). The SF-MPQ
showed us that the descriptors most used by the studied
population were sore/aching, nagging and troublesome. In
agreement with our findings, in a study of 453 Norwegian
cancer patients, the most commonly used descriptor for pain




Mean SD Mean SD Mean SD
Without MTX
Functional Scales 69.3a 16.6 54.0b 18.6 50.3b 22.0 0.003*
Physical functioning 81.2a 13.7 64.0b 23.4 56.4b 19.8 o0.001*
Role functioning 43.8 29.3 32.1 32.7 33.3 36.5 0.370
Cognitive functioning 73.2 30.9 58.9 31.2 65.1 34.5 0.246
Emotional functioning 58.9a 31.2 40.2b 25.7 34.1b 23.7 0.014*
Social functioning 83.3 29.0 73.8 35.3 69.7 35.6 0.402
Symptom Scales 22.1a 15.2 30.3ab 16.8 39.4b 15.1 0.009*
Global Health Scales 60.1 21.8 51.8 24.1 52.3 32.9 0.416
KPS 92.9a 6.6 86.1b 10.7 80.0b 13.4 0.001*
Loco-regional MTX
Functional Scales 24.1 13.3 73.6 14.5 38.2 14.8 0.321
Physical functioning 73.6 22.1 67.5 21.1 66.7 21.1 0.295
Role functioning 40.2 30.3 41.7 32.5 30.3 21.8 0.249
Cognitive functioning 74.0 27.4 80.1 23.7 70.2 27.7 0.264
Emotional functioning 57.9 28.9 58.3 28.2 47.3 29.7 0.228
Social functioning 80.5 27.9 75.7 31.0 85.7 25.9 0.347
Symptom Scales 27.5a 13.9 33.6ab 14.3 23.5b 16.8 0.015*
Global Health Scales 59.3 20.8 60.1 21.9 55.9 20.3 0.698
KPS 88.5a 7.3 87.4a 9.7 82.5b 8.8 0.013*
Distant MTX
Functional Scales 61.7a 15.4 56.1ab 16.8 47.9b 17.3 0.009*
Physical functioning 65.6a 22.7 56.3ab 26.1 45.6b 29.0 0.024*
Role functioning 39.5 33.9 56.3 26.1 19.2 28.0 0.061
Cognitive functioning 76.3 25.0 65.6 32.7 73.5 29.3 0.317
Emotional functioning 53.5 31.2 52.8 25.5 39.3 26.9 0.048
Social functioning 76.3 30.1 80.1 24.7 73.9 34.8 0.625
Symptom Scales 23.6a 10.5 37.5b 16.8 50.0c 20.1 o0.001*
Global Health Scales 50.0a 20.2 55.5ab 20.6 39.7b 24.7 0.006*
KPS 78.9a 8.7 75.5a 69.0 69.0b 13.9 0.040*
Metastasis = MTX * ANOVA - test.
a,ab,b: Tukey test - the means of the different letters are statistically significant.
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was aching (36). Data obtained from another study found
that the most common descriptors were throbbing and tiring-
exhausting (19,31,35).
When analyzing the association between the presence of
pain and the EORTC domains, it was determined that pain
negatively influenced QoL. This was true for the patients
with and without MTX. The Global Health scale showed that
women in pain considered themselves less healthy overall
compared to those without pain (p=0.002).
The effect of pain on QoL is not only related to the intensity
of pain experienced by patients but also to how pain is
perceived in its multidimensional aspect (16,17,37). Our find-
ings identified that patients who classified their pain as
intense and suffered from MTX had lower mean values on
the Global Health Scale. The results clearly show that the
group of patients with distant MTX with acute pain was
strongly associated with a decrease in QoL.
Pain seemed to impact QoL primarily in patients with
distant MTX. These patients not only deal with acute pain
but also have significant impairment of the Functional and
Symptom Scales. They also suffer from poor body image and
are emotionally scarred by the process of treatment and lack
of functional capacity. The latter may be because the patient
is often disfigured by the palliative treatments made neces-
sary by advanced disease (38).
In addition, the perception of pain may contribute to a
warped self-image due to the limbic system’s influence on
the complexity of pain behavior. Corroborating our findings,
a survey of 1965 women with BC conducted in Australia
found sexual function to be reduced due to pain and nega-
tive body image (39).
Interestingly, among those without MTX, those with pain
had lower means than those without for the Future Perspec-
tives item. We believe that this reflects the fact that pain is
one of the most feared symptoms, and its presence causes
patients worry about its possible cause. This may lead to
further worrying about the possibility of MTX and disease
progression and consequently one’s mortality. The Relationship
between QoL and pain seems to be inversely proportional
because the higher the pain, the lower the QoL. In accor-
dance with our results, the study by Nesvold et al. (40)
identified a significant relationship between the related arm
and shoulder problems of women with BC and QoL. It is
interesting to note that among those without MTX, those
with pain had lower means than those without pain for
the Future Perspectives item. We believe that this reflects the
fact that pain is one of the most feared symptoms, and its
presence causes patients worry about its possible cause. This
may lead to further worrying about the possibility of MTX
and disease progression and consequently one’s mortality.
Despite these interesting findings, the present study
should be interpreted with caution in light of its limitations.
Pain was evaluated based on self-assessment and included
estimates in relation to length of time, without the use of
physical parameters. We recognize that some treatments by
themselves can highly influence pain and QoL of these
patients, and the correlation of these parameters with the
results would be desirable; however, the heterogeneity of the
used protocols made that impossible. Therefore, the results
do not take into account the influence of confounding factors
and the sample homogeneity. Further studies using different
approaches with longitudinal design may provide better
explanations of the complex manifestation of breast cancer.
BC is the most frequent cancer in women worldwide, and
pain is one of the most common symptoms, compromising
QoL. In this study, pain was highly prevalent and was
detected in 71% of the patients. These findings are significant
and justify more attention in the management of these
patients in daily practice to minimize this unpleasant
symptom that damages functional capacity and haunts the
patients emotionally.
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Mean SD Mean SD Mean SD
Without MTX
Symptom Scales 26.1 17.7 33.2 17.8 37.6 20.6 0.154
Systemic therapy side effects 30.3 24.1 35.9 25.9 39.8 21.8 0.495
Breast symptoms 32.4 18.3 34.8 20.8 32.6 29.9 0.908
Arm symptoms 14.7a 18.4 31.7a 25.4 45.5b 21.3 o0.001*
Upset by hair loss 5.9 43.6 11.9 53.4 18.2 58.4 0.779
Loco-regional MTX
Symptom Scales 30.7 14.8 32.3 15.0 26.3 13.5 0.225
Systemic therapy side effects 31.0 18.4 38.0 23.4 26.5 21.0 0.073
Breast symptoms 39.0 20.2 30.8 19.5 32.1 19.2 0.145
Arm symptoms 27.0 20.0 26.1 19.8 26.0 19.6 0.974
Upset by hair loss 12.2 22.1 12.3 25.7 7.1 18.9 0.591
Distant MTX
Symptom Scales 22.6a 10.8 24.3b 13.8 32.1b 14.8 0.012*
Systemic therapy side effects 24.8 14.5 27.9 19.9 36.1 18.5 0.046
Breast symptoms 27.2 14.4 27.7 19.2 29.1 27.4 0.939
Arm symptoms 22.2a 22.2 21.7b 17.9 40.7b 29.4 0.001*
Upset by hair loss 10.5 31.5 7.1 42.2 10.3 42.7 0.920
Metastasis = MTX * ANOVA -test.
a,ab,b: Tukey test - the means of the different letters are statistically significant.
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the data, discussing the results, producing the ﬁnal revisions and submitting
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